<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02394951</url>
  </required_header>
  <id_info>
    <org_study_id>201501067</org_study_id>
    <nct_id>NCT02394951</nct_id>
  </id_info>
  <brief_title>Pregabalin in CIPN</brief_title>
  <official_title>Investigation of Somatosensory Predictors of Response to Pregabalin in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to investigate certain patient characteristics that would predict the
      response to a currently approved analgesic, pregabalin, in patients with chronic pain due to
      nerve damage caused by chemotherapy. Patients with this painful condition, called
      chemotherapy-induced peripheral neuropathy (CIPN) have a current or recent history of
      chemotherapy with particular chemotherapy agents called taxanes or oxaliplatin. The
      investigators will recruit potential subjects from both the Siteman Cancer Center and the
      Washington University Pain Management Center. Those patients who meet the inclusion and
      satisfy the exclusion criteria will be enrolled. Subjects will undergo mechanical and thermal
      sensitivity testing on their extremities, will provide quality of life information by
      completing questionnaires and will receive pregabalin followed by placebo, or placebo
      followed by pregabalin [crossover design] in order to assess how well the sensory tests
      predict the analgesic effect of pregabalin (compared to placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at the end of 4-week treatment. The slopes (Pearson coefficients) of the correlation obtained from pregabalin vs. placebo will be compared.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Pain Intensity, Measured on 0-10 Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Absolute change in pain intensity on 0-10 numerical rating scale (NRS) from baseline to 4 weeks with pregabalin vs. placebo NRS: 0= no pain, 10= worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NPSI Outcomes</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Change from baseline to week 4 in total NPSI (Neuropathic Pain Symptom Inventory) score The total NPSI score is comprised by adding 5 sub-scores (Burning pain, Pressing pain, Paroxysmal pain, Evoked pain, and Paresthesia/Dysesthesia) and is expressed on a 0-100 scale; 0-minimum (least), and 100 maximum (worst) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPI Outcomes (SEVERITY)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain severity severity score BPI severity score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Problem Index (SPI) Outcomes</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Change from baseline to week 4 in SPI (Sleep Problem Index) score, on 0-100 scale, where 0= best (least) score, and 100= maximum (worst) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPI Outcomes (INTERFERENCE)</measure>
    <time_frame>baseline to week 4</time_frame>
    <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain interference score BPI interference score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain interference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Significant Pain Reduction</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Number of patients who experienced 50% or more reduction in average daily pain (on 0-10 NRS, Numerical Rating Scale, where 0=least pain, 10=worst pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Neuropathy</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Anticonvulsant</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical, matching inactive substance</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18

          2. Distal symmetric pain distribution (both feet, with or without pain in hands).

          3. The pain appeared during or up to 12 weeks after treatment with oxaliplatin,
             paclitaxel, docetaxel or any combination of these.

          4. Score of 4 or more on DN4 (Douleur Neuropathique 4) neuropathic pain questionnaire

          5. Pain duration &gt; 2 months.

          6. Patient report of average daily pain intensity in the last week &gt;3 on 0-10 Numerical
             Rating Scale (NRS).

          7. Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for
             the duration of study participation.

          8. Able and willing to sign an IRB-approved written informed consent.

        Exclusion Criteria:

          1. Hypersensitivity to pregabalin.

          2. Current treatment with pregabalin.

          3. Current treatment with a vinca alkaloid (e.g. vincristine, vinblastine), or CIPN that
             may be associated with previous treatment with a vinca alkaloid.

          4. History of diabetes mellitus or a neurological disorder with any previous signs of
             distal symmetric polyneuropathy.

          5. Moderate to severe renal failure (Creatinine clearance &lt; 30mL/min, by Cockcroft-Gault
             formula).

          6. ALT (alanine aminotransferase) or AST (aspartate aminotransferase ) &gt; 3 times the
             upper limit of normal.

          7. Planned surgeries or radiation treatment within 10 weeks following study inclusion.

          8. Inability to complete pain self-report.

          9. Pregnancy or lactation

         10. Patients with seizure disorders treated with anticonvulsants

         11. Current participation in a trial with another investigational agent.

         12. Concomitant medication as follows:

               -  Subjects treated with gabapentin or other anticonvulsant for neuropathic pain
                  will be required to taper the medication and discontinue for at least 2 weeks
                  prior to study initiation.

               -  Patients on antidepressant treatment for pain or depression (TCAs, SSRI, SNRIs
                  etc. will be allowed to continue their medications provided they have been on a
                  stable dose for at least 4 weeks before study initiation. No dose regimen changes
                  of antidepressants will be allowed during the study period.

               -  Patients on around-the clock opioid treatment (including tramadol) will be
                  allowed to continue their medication provided they have been on a stable dose for
                  at least 4 weeks before study initiation. The maximum allowed dose of opioid will
                  be equivalent to 60mg oral morphine sulphate. Patients with higher doses will be
                  required to taper down their opioid dose to maximum 60mg oral morphine
                  equivalent, and continue on stable dose for 4 weeks before enrollment in the
                  study. Short-acting opioids for painful CIPN treatment will not be allowed.

               -  Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) will be
                  discontinued at least 2 weeks before study initiation. However, low-dose aspirin
                  (≤325mg/day) will be allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Haroutounian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine/Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>April 1, 2019</results_first_submitted>
  <results_first_submitted_qc>April 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2019</results_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>simon.haroutounian</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02394951/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin First Then Placebo</title>
          <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
        <group group_id="P2">
          <title>Placebo First Then Pregabalin</title>
          <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin First Then Placebo</title>
          <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
        <group group_id="B2">
          <title>Placebo First Then Pregabalin</title>
          <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.1" spread="8.2"/>
                    <measurement group_id="B2" value="59.9" spread="11.4"/>
                    <measurement group_id="B3" value="62.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</title>
        <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at the end of 4-week treatment. The slopes (Pearson coefficients) of the correlation obtained from pregabalin vs. placebo will be compared.</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spontaneous Pain Intensity as a Function of Baseline MPT</title>
          <description>Correlation between Mechanical Pain Threshold (MPT in mN) at baseline and reduction in spontaneous pain intensity (% reduction on 0-10 NRS) at the end of 4-week treatment. The slopes (Pearson coefficients) of the correlation obtained from pregabalin vs. placebo will be compared.</description>
          <units>Pearson correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0179" lower_limit="-0.0459" upper_limit="0.0101"/>
                    <measurement group_id="O2" value="-0.0172" lower_limit="-0.0514" upper_limit="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Pain Intensity, Measured on 0-10 Numerical Rating Scale (NRS)</title>
        <description>Absolute change in pain intensity on 0-10 numerical rating scale (NRS) from baseline to 4 weeks with pregabalin vs. placebo NRS: 0= no pain, 10= worst pain</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Pain Intensity, Measured on 0-10 Numerical Rating Scale (NRS)</title>
          <description>Absolute change in pain intensity on 0-10 numerical rating scale (NRS) from baseline to 4 weeks with pregabalin vs. placebo NRS: 0= no pain, 10= worst pain</description>
          <units>units on a scale (0-10 NRS)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.13"/>
                    <measurement group_id="O2" value="0.3" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NPSI Outcomes</title>
        <description>Change from baseline to week 4 in total NPSI (Neuropathic Pain Symptom Inventory) score The total NPSI score is comprised by adding 5 sub-scores (Burning pain, Pressing pain, Paroxysmal pain, Evoked pain, and Paresthesia/Dysesthesia) and is expressed on a 0-100 scale; 0-minimum (least), and 100 maximum (worst) score</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NPSI Outcomes</title>
          <description>Change from baseline to week 4 in total NPSI (Neuropathic Pain Symptom Inventory) score The total NPSI score is comprised by adding 5 sub-scores (Burning pain, Pressing pain, Paroxysmal pain, Evoked pain, and Paresthesia/Dysesthesia) and is expressed on a 0-100 scale; 0-minimum (least), and 100 maximum (worst) score</description>
          <units>units on a scale (0-100 NPSI score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="12.49"/>
                    <measurement group_id="O2" value="1.8" spread="20.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BPI Outcomes (SEVERITY)</title>
        <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain severity severity score BPI severity score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain severity</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BPI Outcomes (SEVERITY)</title>
          <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain severity severity score BPI severity score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain severity</description>
          <units>units on a scale (0-10 BPI severity)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.52"/>
                    <measurement group_id="O2" value="-0.1" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Problem Index (SPI) Outcomes</title>
        <description>Change from baseline to week 4 in SPI (Sleep Problem Index) score, on 0-100 scale, where 0= best (least) score, and 100= maximum (worst) score</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Problem Index (SPI) Outcomes</title>
          <description>Change from baseline to week 4 in SPI (Sleep Problem Index) score, on 0-100 scale, where 0= best (least) score, and 100= maximum (worst) score</description>
          <units>units on a scale (0-100 SPI)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="9.45"/>
                    <measurement group_id="O2" value="-4.1" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BPI Outcomes (INTERFERENCE)</title>
        <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain interference score BPI interference score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain interference</description>
        <time_frame>baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BPI Outcomes (INTERFERENCE)</title>
          <description>Change from baseline to week 4 in BPI (Brief Pain Inventory) pain interference score BPI interference score is expressed on 0-10 scale, with 0 being the minimum (least), and 10 being the maximum (worst) pain interference</description>
          <units>units on a scale (0-10 BPI interference)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.64"/>
                    <measurement group_id="O2" value="-0.2" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Significant Pain Reduction</title>
        <description>Number of patients who experienced 50% or more reduction in average daily pain (on 0-10 NRS, Numerical Rating Scale, where 0=least pain, 10=worst pain)</description>
        <time_frame>Baseline to week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Significant Pain Reduction</title>
          <description>Number of patients who experienced 50% or more reduction in average daily pain (on 0-10 NRS, Numerical Rating Scale, where 0=least pain, 10=worst pain)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 weeks</time_frame>
      <desc>Common Terminology Criteria for Adverse Events – CTCAE version 4.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin</title>
          <description>Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
Pregabalin: Anticonvulsant
Placebo: Identical, matching inactive substance</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <description>Small bowel obstruction in the setting of a new oncological diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE 4.0">Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Spasticity</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to slow recruitment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Simon Haroutounian</name_or_title>
      <organization>Washington University in Saint Louis</organization>
      <phone>3143622628</phone>
      <email>sharout@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

